Skip to main content

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Wed Mar 4, 7:35AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report), Immunic (IMUX – Research Report) and Apogee Therapeutics (APGE – Research Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

BioMarin Pharmaceutical (BMRN)

Truist Financial analyst Joon Lee maintained a Buy rating on BioMarin Pharmaceutical today. The company’s shares closed last Monday at $59.74.

According to TipRanks.com, Lee is a top 100 analyst with an average return of 35.1% and a 56.8% success rate. Lee covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ultragenyx Pharmaceutical, and Vertex Pharmaceuticals. ;'>

Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $89.93, a 48.1% upside from current levels. In a report issued on February 18, Wells Fargo also maintained a Buy rating on the stock with a $75.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Immunic (IMUX)

In a report released yesterday, Myles Minter from William Blair maintained a Buy rating on Immunic. The company’s shares closed last Monday at $1.06, close to its 52-week low of $0.92.

According to TipRanks.com, Minter is a 5-star analyst with an average return of 32.0% and a 60.9% success rate. Minter covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Neumora Therapeutics, Inc., and Entrada Therapeutics Inc. ;'>

Currently, the analyst consensus on Immunic is a Strong Buy with an average price target of $3.67, a 270.9% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.

Apogee Therapeutics (APGE)

Canaccord Genuity analyst Edward Nash maintained a Buy rating on Apogee Therapeutics today and set a price target of $89.00. The company’s shares closed last Monday at $70.92.

According to TipRanks.com, Nash is a 5-star analyst with an average return of 24.4% and a 47.7% success rate. Nash covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Madrigal Pharmaceuticals, and Kiniksa Pharmaceuticals. ;'>

Apogee Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $105.54, which is a 56.7% upside from current levels. In a report released yesterday, UBS also maintained a Buy rating on the stock with a $100.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).